Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies

Andrew R. MacRae, Peter A. Kavsak, Viliam Lustig, Rakesh Bhargava, Rudy Vandersluis, Glenn E. Palomaki, Marie Jeanne Yerna, Allan S Jaffe

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Background: The American Heart Association (AHA) case definition for acute myocardial infarction (AMI) requires an "adequate set" of biomarkers: 2 measurements of the same marker at least 6 h apart. A sensitive troponin assay might detect significant changes in concentration earlier. We determined AMI prevalence, using protocols with shorter intervals between measurements, with and without incorporating the time from onset of symptoms. Methods: The AHA case definition was used to retrospectively assign a diagnosis in 258 patients presenting to the emergency department with symptoms of cardiac ischemia. AMI was diagnosed if either specimen in an adequate set had a cardiac troponin I (cTnI) above the 99th percentile (AccuTnI® >0.04 μg/L; Beckman Coulter) with a ≥20% change in concentration between specimens. We assessed positivity for AMI after progressively decreasing the time interval between specimens in specimen sets. In addition, for each patient, 2 additional specimen pairs were selected: pairs collected at least 1 h apart with 1 specimen being either 2:3 h after onset or ≥6 h after onset. Results: When we used the AHA definition, the AMI prevalence was 35.7%. Prevalence was not significantly diminished when the interval between specimens was ≥5, ≥4, or ≥3 h (36.4%, 34.5%, and 33.7%, respectively) compared with the AHA ≥6 h interval. When the time from onset of symptoms was included in the specimen selection algorithm, a 1-h interval was sufficient provided that at least one specimen was collected ≥6 h after onset (prevalence, 34.1%; P = 0.48 vs AHA definition). Conclusion: A sensitive cTnI assay in specimen sets with time intervals 23 h, or having one specimen ≥6 h after onset, gave an AMI prevalence equivalent to the AHA definition.

Original languageEnglish (US)
Pages (from-to)812-818
Number of pages7
JournalClinical Chemistry
Volume52
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Epidemiology
American Heart Association
Myocardial Infarction
Research
Troponin I
Assays
Troponin
Biomarkers
Clinical Studies
Hospital Emergency Service
Ischemia

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. / MacRae, Andrew R.; Kavsak, Peter A.; Lustig, Viliam; Bhargava, Rakesh; Vandersluis, Rudy; Palomaki, Glenn E.; Yerna, Marie Jeanne; Jaffe, Allan S.

In: Clinical Chemistry, Vol. 52, No. 5, 05.2006, p. 812-818.

Research output: Contribution to journalArticle

MacRae, Andrew R. ; Kavsak, Peter A. ; Lustig, Viliam ; Bhargava, Rakesh ; Vandersluis, Rudy ; Palomaki, Glenn E. ; Yerna, Marie Jeanne ; Jaffe, Allan S. / Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. In: Clinical Chemistry. 2006 ; Vol. 52, No. 5. pp. 812-818.
@article{4685d182f7ef443faa02ce540f996056,
title = "Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies",
abstract = "Background: The American Heart Association (AHA) case definition for acute myocardial infarction (AMI) requires an {"}adequate set{"} of biomarkers: 2 measurements of the same marker at least 6 h apart. A sensitive troponin assay might detect significant changes in concentration earlier. We determined AMI prevalence, using protocols with shorter intervals between measurements, with and without incorporating the time from onset of symptoms. Methods: The AHA case definition was used to retrospectively assign a diagnosis in 258 patients presenting to the emergency department with symptoms of cardiac ischemia. AMI was diagnosed if either specimen in an adequate set had a cardiac troponin I (cTnI) above the 99th percentile (AccuTnI{\circledR} >0.04 μg/L; Beckman Coulter) with a ≥20{\%} change in concentration between specimens. We assessed positivity for AMI after progressively decreasing the time interval between specimens in specimen sets. In addition, for each patient, 2 additional specimen pairs were selected: pairs collected at least 1 h apart with 1 specimen being either 2:3 h after onset or ≥6 h after onset. Results: When we used the AHA definition, the AMI prevalence was 35.7{\%}. Prevalence was not significantly diminished when the interval between specimens was ≥5, ≥4, or ≥3 h (36.4{\%}, 34.5{\%}, and 33.7{\%}, respectively) compared with the AHA ≥6 h interval. When the time from onset of symptoms was included in the specimen selection algorithm, a 1-h interval was sufficient provided that at least one specimen was collected ≥6 h after onset (prevalence, 34.1{\%}; P = 0.48 vs AHA definition). Conclusion: A sensitive cTnI assay in specimen sets with time intervals 23 h, or having one specimen ≥6 h after onset, gave an AMI prevalence equivalent to the AHA definition.",
author = "MacRae, {Andrew R.} and Kavsak, {Peter A.} and Viliam Lustig and Rakesh Bhargava and Rudy Vandersluis and Palomaki, {Glenn E.} and Yerna, {Marie Jeanne} and Jaffe, {Allan S}",
year = "2006",
month = "5",
doi = "10.1373/clinchem.2005.059550",
language = "English (US)",
volume = "52",
pages = "812--818",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "5",

}

TY - JOUR

T1 - Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies

AU - MacRae, Andrew R.

AU - Kavsak, Peter A.

AU - Lustig, Viliam

AU - Bhargava, Rakesh

AU - Vandersluis, Rudy

AU - Palomaki, Glenn E.

AU - Yerna, Marie Jeanne

AU - Jaffe, Allan S

PY - 2006/5

Y1 - 2006/5

N2 - Background: The American Heart Association (AHA) case definition for acute myocardial infarction (AMI) requires an "adequate set" of biomarkers: 2 measurements of the same marker at least 6 h apart. A sensitive troponin assay might detect significant changes in concentration earlier. We determined AMI prevalence, using protocols with shorter intervals between measurements, with and without incorporating the time from onset of symptoms. Methods: The AHA case definition was used to retrospectively assign a diagnosis in 258 patients presenting to the emergency department with symptoms of cardiac ischemia. AMI was diagnosed if either specimen in an adequate set had a cardiac troponin I (cTnI) above the 99th percentile (AccuTnI® >0.04 μg/L; Beckman Coulter) with a ≥20% change in concentration between specimens. We assessed positivity for AMI after progressively decreasing the time interval between specimens in specimen sets. In addition, for each patient, 2 additional specimen pairs were selected: pairs collected at least 1 h apart with 1 specimen being either 2:3 h after onset or ≥6 h after onset. Results: When we used the AHA definition, the AMI prevalence was 35.7%. Prevalence was not significantly diminished when the interval between specimens was ≥5, ≥4, or ≥3 h (36.4%, 34.5%, and 33.7%, respectively) compared with the AHA ≥6 h interval. When the time from onset of symptoms was included in the specimen selection algorithm, a 1-h interval was sufficient provided that at least one specimen was collected ≥6 h after onset (prevalence, 34.1%; P = 0.48 vs AHA definition). Conclusion: A sensitive cTnI assay in specimen sets with time intervals 23 h, or having one specimen ≥6 h after onset, gave an AMI prevalence equivalent to the AHA definition.

AB - Background: The American Heart Association (AHA) case definition for acute myocardial infarction (AMI) requires an "adequate set" of biomarkers: 2 measurements of the same marker at least 6 h apart. A sensitive troponin assay might detect significant changes in concentration earlier. We determined AMI prevalence, using protocols with shorter intervals between measurements, with and without incorporating the time from onset of symptoms. Methods: The AHA case definition was used to retrospectively assign a diagnosis in 258 patients presenting to the emergency department with symptoms of cardiac ischemia. AMI was diagnosed if either specimen in an adequate set had a cardiac troponin I (cTnI) above the 99th percentile (AccuTnI® >0.04 μg/L; Beckman Coulter) with a ≥20% change in concentration between specimens. We assessed positivity for AMI after progressively decreasing the time interval between specimens in specimen sets. In addition, for each patient, 2 additional specimen pairs were selected: pairs collected at least 1 h apart with 1 specimen being either 2:3 h after onset or ≥6 h after onset. Results: When we used the AHA definition, the AMI prevalence was 35.7%. Prevalence was not significantly diminished when the interval between specimens was ≥5, ≥4, or ≥3 h (36.4%, 34.5%, and 33.7%, respectively) compared with the AHA ≥6 h interval. When the time from onset of symptoms was included in the specimen selection algorithm, a 1-h interval was sufficient provided that at least one specimen was collected ≥6 h after onset (prevalence, 34.1%; P = 0.48 vs AHA definition). Conclusion: A sensitive cTnI assay in specimen sets with time intervals 23 h, or having one specimen ≥6 h after onset, gave an AMI prevalence equivalent to the AHA definition.

UR - http://www.scopus.com/inward/record.url?scp=33646359452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646359452&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.059550

DO - 10.1373/clinchem.2005.059550

M3 - Article

C2 - 16556688

AN - SCOPUS:33646359452

VL - 52

SP - 812

EP - 818

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 5

ER -